Cargando…
Acquired Factor V Inhibitor After Antibiotic Therapy: A Clinical Case Report and Review of the Literature
Acquired factor V inhibitor (aFVi) is an exceptionally rare hematologic condition that can range from incidental laboratory abnormalities to life-threatening hemorrhage. Bovine thrombin was formerly the most common cause of this condition; however, the decreased use of bovine thrombin in surgical pr...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455466/ https://www.ncbi.nlm.nih.gov/pubmed/32874809 http://dx.doi.org/10.7759/cureus.9481 |
_version_ | 1783575631990095872 |
---|---|
author | Chartier, Alexander R Hillert, Conor J Gill, Harpreet Jha, Pinky |
author_facet | Chartier, Alexander R Hillert, Conor J Gill, Harpreet Jha, Pinky |
author_sort | Chartier, Alexander R |
collection | PubMed |
description | Acquired factor V inhibitor (aFVi) is an exceptionally rare hematologic condition that can range from incidental laboratory abnormalities to life-threatening hemorrhage. Bovine thrombin was formerly the most common cause of this condition; however, the decreased use of bovine thrombin in surgical procedures has led to a shift in the cause of aFVi toward antibiotic use and malignancies. Here we present a case of an 80-year-old Caucasian female on long-term warfarin therapy who presented with epistaxis and an elevated international normalized ratio, and a history of cephalosporin antibiotic use. We review the published literature beginning in 2016 to identify the evolving causes of aFVi. Additionally, we propose that stress-mediated immune regulation may contribute to antibody formation, preventing the interaction between factor V and the damaged phospholipid membranes. This case highlights the evolving causes of aFVi and should prompt physicians to consider this diagnosis in coagulopathies that do not correct with traditional therapies. |
format | Online Article Text |
id | pubmed-7455466 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-74554662020-08-31 Acquired Factor V Inhibitor After Antibiotic Therapy: A Clinical Case Report and Review of the Literature Chartier, Alexander R Hillert, Conor J Gill, Harpreet Jha, Pinky Cureus Hematology Acquired factor V inhibitor (aFVi) is an exceptionally rare hematologic condition that can range from incidental laboratory abnormalities to life-threatening hemorrhage. Bovine thrombin was formerly the most common cause of this condition; however, the decreased use of bovine thrombin in surgical procedures has led to a shift in the cause of aFVi toward antibiotic use and malignancies. Here we present a case of an 80-year-old Caucasian female on long-term warfarin therapy who presented with epistaxis and an elevated international normalized ratio, and a history of cephalosporin antibiotic use. We review the published literature beginning in 2016 to identify the evolving causes of aFVi. Additionally, we propose that stress-mediated immune regulation may contribute to antibody formation, preventing the interaction between factor V and the damaged phospholipid membranes. This case highlights the evolving causes of aFVi and should prompt physicians to consider this diagnosis in coagulopathies that do not correct with traditional therapies. Cureus 2020-07-30 /pmc/articles/PMC7455466/ /pubmed/32874809 http://dx.doi.org/10.7759/cureus.9481 Text en Copyright © 2020, Chartier et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Hematology Chartier, Alexander R Hillert, Conor J Gill, Harpreet Jha, Pinky Acquired Factor V Inhibitor After Antibiotic Therapy: A Clinical Case Report and Review of the Literature |
title | Acquired Factor V Inhibitor After Antibiotic Therapy: A Clinical Case Report and Review of the Literature |
title_full | Acquired Factor V Inhibitor After Antibiotic Therapy: A Clinical Case Report and Review of the Literature |
title_fullStr | Acquired Factor V Inhibitor After Antibiotic Therapy: A Clinical Case Report and Review of the Literature |
title_full_unstemmed | Acquired Factor V Inhibitor After Antibiotic Therapy: A Clinical Case Report and Review of the Literature |
title_short | Acquired Factor V Inhibitor After Antibiotic Therapy: A Clinical Case Report and Review of the Literature |
title_sort | acquired factor v inhibitor after antibiotic therapy: a clinical case report and review of the literature |
topic | Hematology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455466/ https://www.ncbi.nlm.nih.gov/pubmed/32874809 http://dx.doi.org/10.7759/cureus.9481 |
work_keys_str_mv | AT chartieralexanderr acquiredfactorvinhibitorafterantibiotictherapyaclinicalcasereportandreviewoftheliterature AT hillertconorj acquiredfactorvinhibitorafterantibiotictherapyaclinicalcasereportandreviewoftheliterature AT gillharpreet acquiredfactorvinhibitorafterantibiotictherapyaclinicalcasereportandreviewoftheliterature AT jhapinky acquiredfactorvinhibitorafterantibiotictherapyaclinicalcasereportandreviewoftheliterature |